Vaupel P, Schlenger K, Knoop C, Hockel M: Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res. 1991, 51: 3316-3322.
CAS
PubMed
Google Scholar
Hohenberger P, Felgner C, Haensch W, Schlag PM: Tumor oxygenation correlates with molecular growth determinants in breast cancer. Breast Cancer Res Treat. 1998, 48: 97-106. 10.1023/A:1005921513083.
Article
CAS
PubMed
Google Scholar
Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Moldofsky PJ, Hartz WH, Broder GJ: Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys. 1988, 14: 831-838.
Article
CAS
PubMed
Google Scholar
Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P: Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996, 56: 4509-4515.
CAS
PubMed
Google Scholar
Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW: Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1997, 38: 285-289. 10.1016/S0360-3016(97)00101-6.
Article
CAS
PubMed
Google Scholar
Okunieff P, Hoeckel M, Dunphy EP, Schlenger K, Knoop C, Vaupel P: Oxygen tension distributions are sufficient to explain the local response of human breast tumors treated with radiation alone. Int J Radiat Oncol Biol Phys. 1993, 26: 631-636.
Article
CAS
PubMed
Google Scholar
Lyng H, Rofstad EK: Treatment failure following sequential thermo-radiotherapy of locally advanced breast carcinoma occurs primarily in poorly vascularized tumors. Oncology. 1995, 52: 443-447.
Article
CAS
PubMed
Google Scholar
Hill RP, Stanley JA: The response of hypoxic B16 melanoma cells to in vivo treatment with chemotherapeutic agents. Cancer Res. 1975, 35: 1147-1153.
CAS
PubMed
Google Scholar
Teicher BA, Lazo JS, Sartorelli AC: Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res. 1981, 41: 73-81.
CAS
PubMed
Google Scholar
Teicher BA: Hypoxia and drug resistance. Cancer Metastasis Rev. 1994, 13: 39-68.
Article
Google Scholar
Ojugo AS, McSheehy PM, Stubbs M, Alder G, Bashford CL, Maxwell RJ, Leach MO, Judson IR, Griffiths JR: Influence of pH on the uptake of 5-fluorouracil into isolated tumour cells. Br J Cancer. 1998, 77: 873-879.
Article
CAS
PubMed
PubMed Central
Google Scholar
Denny WA, Wilson WR: Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia. Expert Opin Investig Drugs. 2000, 9: 2889-2901.
Article
CAS
PubMed
Google Scholar
Johnson CA, Kilpatrick D, von Roemeling R, Langer C, Graham MA, Greenslade D, Kennedy G, Keenan E, O'Dwyer PJ: Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors. J Clin Oncol. 1997, 15: 773-780.
Article
CAS
PubMed
Google Scholar
Marin A, Lopez de Cerain A, Hamilton E, Lewis AD, Martinez-Penuela JM, Idoate MA, Bello J: DT-diaphorase and cytochrome B5 reductase in human lung and breast tumours. Br J Cancer. 1997, 76: 923-929.
Article
CAS
PubMed
Google Scholar
Lopez de Cerain A, Marin A, Idoate MA, Tunon MT, Bello J: Carbonyl reductase and NADPH cytochrome P450 reductase activities in human tumoral versus normal tissues. Eur J Cancer. 1999, 35: 320-324. 10.1016/S0959-8049(98)00372-4.
Article
CAS
PubMed
Google Scholar
Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, van der Wall E: Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst. 2001, 93: 309-314. 10.1093/jnci/93.4.309.
Article
CAS
PubMed
Google Scholar
Dachs GU, Patterson AV, Firth JD, Ratcliffe PJ, Townsend KMS, Stratford IJ, Harris AL: Targeting gene expression to hypoxic tumour cells. Nat Med. 1997, 3: 515-520.
Article
CAS
PubMed
Google Scholar
Koshikawa N, Takenaga K, Tagawa M, Sakiyama S: Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumour cells. Cancer Res. 2000, 60: 2936-2941.
CAS
PubMed
Google Scholar
Lemmon MJ, van Zijl P, Fox ME, Mauchline ML, Giaccia AJ, Minton NP, Brown JM: Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther. 1997, 4: 791-796. 10.1038/sj/gt/3300468.
Article
CAS
PubMed
Google Scholar
Greco O, Folkes LK, Wardman P, Tozer GM, Dachs GU: Development of a novel enzyme/prodrug combination for gene therapy of cancer: horseradish peroxidase/indole-3-acetic acid. Cancer Gene Ther. 2000, 7: 1414-1420. 10.1038/sj/cgt/7700258.
Article
CAS
PubMed
Google Scholar
Patterson LH, McKeown SR, Robson T, Gallagher R, Raleigh SM, Orr S: Antitumour prodrug development using cytochrome P450 (CYP) mediated activation. Anticancer Drug Des. 1999, 14: 473-486.
CAS
PubMed
Google Scholar
Warrington KH, Teschendorf C, Cao L, Muzyczka N, Siemann DW: Developing VDEPT for DT-diaphorase (NQO1) using an AAV vector plasmid. Int J Radiat Oncol Biol Phys. 1998, 42: 909-912. 10.1016/S0360-3016(98)00357-5.
Article
CAS
PubMed
Google Scholar
Patterson AV, Barham HM, Chinje EC, Adams GE, Harris AL, Stratford IJ: Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Br J Cancer. 1995, 72: 1144-1150.
Article
CAS
PubMed
PubMed Central
Google Scholar
Patterson AV, Saunders M, Chinje EC, Talbot DC, Harris AL, Stratford IJ: Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR4233) and RSU1069. Br J Cancer. 1997, 76: 1338-1347.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jounaidi Y, Waxman DJ: Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. Cancer Res. 2000, 60: 3761-3769.
CAS
PubMed
Google Scholar
Hernandez-Alcoceba R, Pihalja M, Nunez G, Clarke MF: Evaluation of a new dual-specificity promoter for selective induction of apoptosis in breast cancer cells. Cancer Gene Ther. 2001, 8: 298-307. 10.1038/sj.cgt.7700304.
Article
CAS
PubMed
Google Scholar
Pandha HS, Martin LA, Rigg A, Hurst HC, Stamp GW, Sikora K, Lemoine NR: Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression. J Clin Oncol. 1999, 17: 2180-2189.
Article
CAS
PubMed
Google Scholar
Yazawa K, Fujimori M, Amano J, Kano Y, Taniguchi S: Bifidobacterium longum as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors. Cancer Gene Ther. 2000, 7: 269-274. 10.1038/sj/cgt/7700122.
Article
CAS
PubMed
Google Scholar
Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V, Seymour LW: Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. 2001, 8: 341-348. 10.1038/sj/gt/3301389.
Article
CAS
PubMed
Google Scholar
Griffiths L, Binley K, Iqball S, Kan O, Maxwell P, Ratcliffe P, Lewis C, Harris A, Kingsman S, Naylor S: The macrophage – a novel system to deliver gene therapy to pathological hypoxia. Gene Ther. 2000, 7: 255-262. 10.1038/sj/gt/3301058.
Article
CAS
PubMed
Google Scholar
Raleigh JA, Chou SC, Arteel GE, Horsman MR: Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat Res. 1999, 151: 580-589.
Article
CAS
PubMed
Google Scholar
Airley R, Loncaster J, Davidson S, Bromley M, Roberts S, Patterson A, Hunter R, Stratford I, West C: Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res. 2001, 7: 928-934.
CAS
PubMed
Google Scholar
Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, Gatter KC, Ratcliffe PJ, Harris AL: Prognostic significance of a novel hypoxia regulated marker – carbonic anhydrase IX in invasive breast carcinoma. J Clin Oncol. 2001
Google Scholar
Yang DJ, Ilgan S, Higuchi T, Zareneyrizi F, Oh CS, Liu CW, Kim EE, Podoloff DA: Noninvasive assessment of tumor hypoxia with 99mTc labeled metronidazole. Pharm Res. 1999, 16: 743-750. 10.1023/A:1018836911013.
Article
CAS
PubMed
Google Scholar